Naim Farhat, MD
Interventional Cardiology · Elyria, OHNPI 1881673234
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $8,553 of the $12,638 with a category attached, or 67.7%. Medtronic accounts for 73.7% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2019 at $9,026 and has fallen 93.5% since, to $584 in 2025.
Across 113 payments — averaging $111.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$9K
- Abbott$920
- Abiomed$556
- Atricure, Inc.$454
- W. L. Gore & Associates, Inc.$450
- Novartis$163
- plus $776 from 21 others
Across 136 payments — averaging $6459.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$700K
- CSL Behring$165K
- Abbott$6K
- Philips North America LLC$4K
- Surmodics, Inc.$3K
What the payments were for
- Consulting fees$90%
- Speaking & faculty fees$4504%
- Travel & lodging$8,55368%
- Food & beverage$3,62629%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 40 | $9,319 |
| Abbott | 10 | $920 |
| Abiomed | 4 | $556 |
| Atricure, Inc. | 8 | $454 |
| W. L. Gore & Associates, Inc. | 1 | $450 |
| Novartis | 10 | $163 |
| E.r. Squibb & Sons, L.L.C. | 6 | $111 |
| Heartflow, Inc. | 1 | $108 |
| AstraZeneca | 3 | $61 |
| Johnson & Johnson | 4 | $58 |
| Pfizer | 4 | $48 |
| Boehringer Ingelheim | 3 | $48 |
| Gilead | 2 | $44 |
| Cardiovascular Systems Inc. | 2 | $40 |
| Cardiva Medical, Inc. | 2 | $38 |
| Novo Nordisk | 2 | $31 |
| Lexicon Pharmaceuticals, Inc. | 1 | $30 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $22 |
| Amgen | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
| Cordis US CORP. | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Philips North America LLC | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Terumo Medical Corporation | 1 | $13 |
| Z-medica, LLC | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Resolute$8,051
- Impella$477
- Product in Development$450
- SYNERGY ABLATION SYSTEM$313
- MitraClip$294
- AMPLATZER AMULET$143
- ONYX FRONTIER$133
- CoreValve Evolut$122
- CardioMEMS HF System$122
- XIENCE SIERRA$119
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$109
- FFRct$108
How this compares
$12,638 in reported general payments places this provider in the 70th percentile of 256 interventional cardiology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 320 | $397,845 |
| XareltoRivaroxaban | 93 | $102,616 |
| EntrestoSacubitril/Valsartan | 67 | $80,916 |
| Repatha SureclickEvolocumab | 59 | $67,526 |
| JardianceEmpagliflozin | 26 | $28,477 |
| Atorvastatin Calcium | 1,089 | $12,574 |
| Ranolazine ErRanolazine | 103 | $10,802 |
| Metoprolol Succinate | 635 | $8,836 |
| Icosapent Ethyl | 15 | $7,354 |
| Losartan Potassium | 587 | $5,974 |
| ClopidogrelClopidogrel Bisulfate | 493 | $5,008 |
| Potassium Chloride | 154 | $3,813 |
| Amlodipine Besylate | 640 | $3,713 |
| Nitroglycerin | 340 | $3,489 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 247 | $3,468 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $48 | $397,845320 claims |
| Johnson & JohnsonXarelto | $58 | $102,61693 claims |
| NovartisEntresto | $163 | $80,91667 claims |
| Boehringer IngelheimJardiance | $48 | $28,47726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 256 interventional cardiology providers in Ohio.
Other interventional cardiology in Elyria
- Gary AnselColumbus$3.3M
- John CheathamColumbus$1.4M
- Carlos Sanchez SotoColumbus$1.1M
- Steven YakubovColumbus$907K
- Timothy HenryCincinnati$605K
- Mitchell SilverColumbus$562K
- John PhillipsColumbus$410K
- John CorlCincinnati$390K
- Santiago GarciaCincinnati$360K
- Atish MathurMansfield$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.